Artificial Intelligence Is Changing How Researchers Approach Drug Development
Developing new medicines is one of the most complex and expensive challenges in healthcare.
Researchers must understand how diseases develop, identify potential treatments, determine which patients may benefit, and conduct clinical trials to evaluate safety and effectiveness.
Even promising discoveries can take years to reach patients, and many experimental treatments never receive regulatory approval.
Artificial intelligence is increasingly being explored as a way to support this process.
On October 23, 2026, New York-based biotechnology company Pathos AI announced a $237 million Series E financing round and new strategic collaborations with Bristol Myers Squibb and Tempus AI.
Together, the announcements highlight growing investment in AI technologies designed to support scientific research and clinical development.
A $237 Million Investment in AI-Powered Biotechnology
Pathos AI announced that its latest financing round was led by Bristol Myers Squibb, with participation from existing investors.
The transaction valued the company at approximately $3 billion following the investment.
Pathos develops an artificial intelligence platform called Foundry, which the company uses to analyze clinical and scientific information and support decisions involving drug development.
The platform incorporates specialized AI agents designed to examine information from multiple sources, including clinical research, biological data, and treatment outcomes.
According to Pathos, its approach is intended to help researchers identify promising therapeutic opportunities, assess patient populations, and make more informed decisions throughout clinical development.
The company plans to use the new financing to expand Foundry and advance its clinical-stage oncology pipeline.
That pipeline includes experimental therapies targeting several types of cancer.
Although the financing represents a significant investment in the company’s strategy, it does not establish that its experimental treatments will ultimately receive regulatory approval.
Expanding AI Research Into Neurological Diseases
Alongside its financing announcement, Pathos unveiled collaborations with Bristol Myers Squibb and Tempus AI.
The partnerships will focus initially on Alzheimer’s disease and other neurological conditions.
Tempus plans to develop a large, de-identified dataset involving hundreds of thousands of patients with neurological disorders.
The dataset is intended to combine information collected over time, potentially allowing researchers to investigate relationships between disease progression, patient characteristics, and treatment outcomes.
Pathos will license the dataset through a five-year agreement valued at $55 million.
The company intends to use Foundry to analyze the information, generate research hypotheses, and support the design of more targeted clinical trials.
Bristol Myers Squibb will contribute its pharmaceutical research and development expertise.
The agreement also provides Bristol Myers Squibb with access to the Foundry platform across its broader research portfolio and certain exclusive rights involving neuroscience development.
Why This Approach Matters
Neurological diseases present significant scientific challenges.
Conditions such as Alzheimer’s involve complex biological processes, and patients can experience different patterns of disease progression.
Researchers often need to evaluate large amounts of information to understand which biological pathways may be relevant and which patients might respond to particular treatments.
AI systems may help scientists identify patterns across datasets that would otherwise require extensive manual analysis.
However, identifying a pattern is not the same as demonstrating that a treatment works.
Research hypotheses must still undergo scientific investigation, and potential medicines require appropriate clinical testing.
The Pathos collaborations represent an investment in the research process, not an announcement of a new approved treatment.
The STEM Careers Behind AI Drug Discovery
The growing intersection of artificial intelligence and biotechnology is creating demand for interdisciplinary expertise.
Computational biologists use software and mathematical models to investigate biological systems.
Bioinformatics specialists organize and analyze complex scientific datasets.
Machine learning engineers develop systems capable of identifying patterns in large quantities of information.
Clinical researchers evaluate experimental treatments and help determine whether scientific findings translate into meaningful patient outcomes.
Other professionals contribute expertise in regulatory affairs, data governance, software engineering, and research operations.
For women pursuing careers in STEM, these overlapping disciplines demonstrate how technical skills can be applied to challenges in healthcare and scientific discovery.
They also illustrate the importance of collaboration between researchers with different backgrounds.
What Comes Next?
Pathos plans to expand its AI platform and continue advancing its experimental drug pipeline.
Its new neuroscience partnerships will involve developing and analyzing specialized patient datasets.
The ultimate impact of these initiatives will depend on the quality of the research, the effectiveness of the technology, and the results of future clinical studies.
For the biotechnology industry, the announcement reflects a broader shift toward combining artificial intelligence, biological research, and pharmaceutical expertise.
For women in STEM, it highlights another area where scientific knowledge and technical innovation are increasingly intersecting.
Sources & Further Reading
Pathos AI — $237 Million Series E Announcement, October 23, 2026
Pathos AI — Bristol Myers Squibb and Tempus AI Collaboration Announcement
Reuters — October 23 Reporting on the Neuroscience Partnerships
Discover more from Fems in STEM
Subscribe to get the latest posts sent to your email.
